

# The Novel Psychoactive Substances Epidemic: a Scientometric Perspective

Michelle Jin Yee Neoh<sup>a</sup>, Alessandro Carollo<sup>b</sup>, Mengyu Lim<sup>a</sup>, Ornella Corazza<sup>b,c</sup>, Aurora Coppola<sup>d</sup>, Gianluca Esposito<sup>b,\*</sup>

<sup>a</sup>*Psychology Program, Nanyang Technological University, Singapore, 639818, Singapore*

<sup>b</sup>*Department of Psychology and Cognitive Science, University of Trento, Rovereto, TN, 38068, Italy*

<sup>c</sup>*School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom*

<sup>d</sup>*Psychology Unit, Azienda Provinciale per i Servizi Sanitari, Trento, Italy, Rovereto, TN, 38068, Italy*

---

## Abstract

The unprecedented proliferation of novel psychoactive substances (NPS) in the illicit drug market has been a public health concern since their emergence in the 2000s. Their consumption can pose a severe health risks as their mechanism of action is poorly understood and their level of toxicity is high mainly due to the diffusion of very potent synthetic cannabinoids and synthetic opioids. This study systemically analyses the evolution of the scientific literature on NPS to gain a better understanding of the areas of major research interests and how they interlink. Findings indicate that the published evidence covers clusters focused on classes of NPS that have received widespread media attention, such as mephedrone and fentanyl, and have largely been concerned with the pharmacological and the toxicological profiles of these substances. This scientometric perspective also provides greater insight into the knowledge gaps within this new and rapidly growing field of study and highlights the need for an interdisciplinary approach in tackling the NPS epidemic.

**Keywords:** document co-citation analysis, novel psychoactive substances, substance use, synthetic cannabinoids, synthetic opioids

---

\*Correspondence: Corso Bettini 31, Rovereto, TN, 38068, Italy.

Email address: [gianluca.esposito@unitn.it](mailto:gianluca.esposito@unitn.it) (Gianluca Esposito)

## 1. Introduction

In recent years, there has been an unprecedented proliferation of novel psychoactive substances (NPS) in the drug market globally with 1124 substances being reported to the United Nations Office on Drugs and Crime by December 2021 [1]. The term NPS is typically used to refer to substances originally designed as legal alternatives to controlled substances, such as analogues of existing controlled drugs and pharmaceutical products designed to mimic their actions and effects [2, 3]. The emergence of NPS in the illicit drug market poses a serious challenge for drug policy and public health. The ease and speed with which NPS are continuously developed and reintroduced in the market as analogues or derivatives with small chemical changes in order to circumvent drug enforcement and legislation makes these substances difficult to legally regulate and control. In addition, the potency, pharmacological effects and risk profiles of NPS are diverse and generally unknown, where users are often misinformed and lack awareness of the contents of the NPS they are consuming. The properties and long-term effects of NPS are not well understood and few studies examining most of these new substances have been published [4].

Adverse health effects including suicide and fatalities have been documented in association with and attributed to NPS use [5] and the most frequent classes of NPS are associated with medical risks [6]. In an analysis of hospital emergency data by the European Drug Emergencies Network, 9% of all drug-related emergencies involved NPS [7]. Reports have also cited correlations between NPS use and increased spread of diseases such as HIV and hepatitis C [8]. Although case reports and case series form the bulk of research informing our understanding of NPS, it is apparent that there are significant health risks associated with NPS use.

Although the prevalence of NPS in the general population appears to be low, their consumption among younger age groups is higher and warrants concern. A systematic review found that most studies showed 3% or less of adult populations reported recent use of NPS, typically in the past year, compared to an estimated 1 in 10 young people [9]. Similarly, an estimated 1-8% of school students have used NPS at some point [10], indicating a wor-

rying trend of drug use among youth. However, it is important to note that such self-report data on NPS use are most likely not an accurate representation of actual market penetration and user uptake of NPS due to the sheer speed in which NPS are introduced to market as well as unwitting consumers.

The aim of this study is to identify the most relevant publications, the nature of their inquiry and associate literature gaps in the field of NPS. We conducted a document co-citation analysis (DCA) [11, 12] to analyse references and the relevance of these publications in the existing literature on NPS. By clustering publications according to common research domains, articles with significant contributions to the literature can be identified while highlighting the coverage and gaps in existing literature. The scientometric results can illuminate research and identifying publication trends, the links between different works and scientific fields involved in the exploration of issues relating to NPS. The scientometric approach has been employed in neuroscience [13] and digital psychology [14].

## 2. Material and Methods

Publications were downloaded from Scopus in accordance with the standard and established scientometric procedures [11]. We used the following search string TITLE-ABS-KEY(“novel psychoactive substanc\*” OR “new psychoactive substanc\*”) AND ( LIMIT-TO ( LANGUAGE , “English” )) and found a total of 2,365 documents published from 1 January 2010 to 13 June 2022. By limiting the search to publications in English, the analysis will be built on international scientific literature in the field, allowing for a more standardised and rigorous examination of existing work [15].

### 2.1. Data import on CiteSpace

Scientometric analysis was conducted using CiteSpace software (Version 6.1.R2) and the articles downloaded from Scopus were imported into the software. 106,911 of a total of 111,855 references (95.58%) cited by the 2,365 articles were valid (Figure 1). A “valid” reference is one that contains seven key pieces of information: author, year of publication, title, source, volume, pages and DOI [11]. Due to irregularities in the citation format, a number of references were considered invalid. Negligible losses in references (1-5%) commonly occur during the data import to the CiteSpace software [16]. The

70 CiteSpace function (Remove Alias) was turned ON to eliminate repeated or  
71 identical entries.




Figure 1: PRISMA flowchart for search criteria and reference eligibility

## 72 2.2. Document Co-Citation Analysis (DCA) and Optimisation of Parameters

73 DCA was conducted to determine the main research domains in NPS  
74 literature. DCA is based on the frequency with which two or more papers  
75 are cited together in source articles [17]. The assumption is that frequent  
76 co-citations among articles reflect common research trends and intellectual  
77 domains in the literature [12, 18]. The network resulting from the DCA is  
78 composed of documents frequently cited together along with the documents  
79 that cite them (i.e. articles downloaded from Scopus).

80 DCA parameters were optimised in order to obtain a balanced network  
81 of documents. Several DCAs were computed and compared, each with a  
82 different setting for one of three node selection criteria; g-index, TOP  $N$ ,  
83 TOP  $N\%$ , as done in [13, 15, 18, 19, 14, 20]. The node selection criteria  
84 are *a priori* settings that define the criterion used for selecting articles to be

85 included in the network, and consequently, determine the final network of  
86 articles being generated. The g-index is a measure of the citation scores of  
87 an author's top publications [21, 22]. It represents the largest number that  
88 equals the average number of citations of the most highly cited g publications  
89 [16]. TOP  $N$  and TOP  $N\%$  are criteria used to select  $N$  and  $N\%$  most  
90 cited within a time slice (1 year was used in this study) as network nodes  
91 respectively [11].

92 In order to generate the final optimal network, node selection criteria were  
93 varied together with their scale factor values, which refer to the chosen nu-  
94 meric values used as thresholds for the respective node selection criteria [14].  
95 Specifically, DCAs with the following node selection criteria were compared:  
96 g-index with scale factor  $k$  set at 10, 15, 25, 50, TOP  $N$  with scale factor  $N$   
97 set at 25, 50 and TOP  $N\%$  with scale factor  $N$  set at 10. To determine the  
98 node selection criteria and scale factor to use for the generation of the final  
99 network, the overall effects on the structural metrics of the generated net-  
100 work, the number of nodes included and clusters identified were compared.  
101 After comparison of these metrics, TOP  $N$  with  $N$  at 25 was the parameter  
102 which was used to generate the final network of articles.

### 103 2.3. Metrics

104 Structural and temporal metrics are used in describing CiteSpace results.  
105 Structural metrics consist of (i) *modularity-Q*, (ii) *silhouette scores* and (iii)  
106 *betweenness centrality*. Modularity-Q values range from 0 to 1 and indicates  
107 the degree to which the network can be decomposed into single groups of  
108 nodes, which are referred to as modules or clusters [23]. High modularity-  
109 Q values indicate a well-structured network [12]. Silhouette scores are a  
110 measure of inner consistency - cohesion and separation - of the modules [24].  
111 Silhouette scores vary from -1 to +1, where higher values represent high  
112 separation from other modules and internal consistency [25]. Betweenness  
113 centrality represents the degree to which a node connects an arbitrary pair of  
114 nodes in the network [11, 26]. Betweenness centrality values range from 0 to  
115 1, where groundbreaking and revolutionary works in the scientific literature  
116 typically score higher [27].

117 Temporal metrics consist of (i) *citation burstness* and (ii) *sigma*. The  
118 Kleinberg's algorithm [28] is used to calculate citation burstness, which in-  
119 dicates a sudden increase in the number of citations of an article in a given  
120 time frame [29]. Sigma is calculated with the equation  $(\text{centrality} + 1)^{\text{burstness}}$

and indicates the novelty of a document and influence on the overall network [30].

The overall configuration of the generated network and identified clusters of references were examined with modularity-Q and silhouette scores. The attributes of single nodes in the network were examined using betweenness centrality and the temporal metrics.

### 3. Results

#### 3.1. Structural metrics

The final optimised network obtained from the DCA consisted of 317 nodes and 1,327 links, indicating an average of 4.15 connections with other references for each node (Figure 2). The network had a modularity-Q index of 0.6181 and a mean silhouette score of 0.8445, indicating medium divisibility of the network into clusters that are highly homogenous.




Figure 2: Network of publications generated through the document co-citation analysis (DCA). The major clusters are grouped by colour.

#### 3.2. Citation burstness

A total of 64 documents were found to exhibit a citation burstness (Table 1). 20 of these documents belong to cluster #0, 13 to cluster #1, 16 to cluster #2, 4 to cluster #3, 3 to cluster #4, 1 to cluster #5, 4 to cluster #6 and 1 to cluster #9. The article with the highest burst strength was authored by Hondebrink et al. in 2015 [31] with a score of 12.43. The burst began in 2017 and ended in 2019. The article with the longest burst duration was

141 authored by Castaneto et al. in 2014 [32] with a burst duration of 5 years  
 142 from 2017 to 2022. The article with the highest sigma value was authored  
 143 by Hermanns-clausen in 2013 [33] with a sigma value of 2.44.

Table 1: Top 15 publications in terms of burst strength.

Reference	Burst	Year	Start of burstness	End of burstness	Burst duration	Centrality	Sigma
Hondebrink et al. [31]	12.43	2015	2017	2019	2	0.01	1.10
Armenian et al. [34]	11.68	2018	2019	2022	3	0.02	1.19
Peacock et al. [9]	10.97	2019	2020	2022	2	0.01	1.08
Brandt et al. [35]	10.93	2014	2016	2017	1	0.00	1.00
Rickli et al. [36]	10.58	2015	2017	2018	1	0.00	1.04
Morris et al. [37]	10.07	2014	2017	2018	1	0.05	1.67
Measham et al. [38]	9.46	2011	2012	2014	2	0.07	1.90
Hermanns-clausen et al. [33]	9.44	2013	2014	2017	3	0.01	2.44
Kraemer et al. [39]	8.62	2019	2020	2022	2	0.02	1.17
Seely et al. [40]	8.51	2012	2015	2018	3	0.04	1.41
Richter et al. [41]	8.26	2017	2019	2020	1	0.00	1.01
Baumann et al. [42]	7.92	2012	2016	2017	1	0.01	1.09
Prosser et al. [43]	7.81	2012	2016	2017	1	0.17	3.50
Majchrzak et al. [44]	7.68	2018	2020	2022	2	0.01	1.12
Favretto et al. [45]	7.55	2013	2015	2017	2	0.01	1.10

### 144 3.3. Thematic clusters

145 Ten major clusters were identified (Figure 2, Table 2). The largest cluster  
 146 #0 consisted of 59 nodes and had a silhouette score of 0.716, where the  
 147 constituent references were published in 2019 on average. The cluster was  
 148 labelled “Mechanisms of NPS action”. Second, cluster #1 consisted of 56  
 149 nodes and had a silhouette score of 0.84, where the constituent references  
 150 were published in 2012 on average. The cluster was labelled “Availability and  
 151 use of NPS”. Third, cluster #2 consisted of 49 nodes and had a silhouette  
 152 score of 0.809, where the constituent references were published in 2014 on  
 153 average. The cluster was labelled “Neuropharmacology of NPS”.

Table 2: Metrics of the 10 clusters identified with the DCA. Log-likelihood Ratio (LLR) labels are automatically generated by the software.

Cluster ID	Size	Silhouette	Mean year	LLR label	Proposed label
0	59	0.716	2019	Synthetic cannabinoid	Mechanisms of NPS action
1	56	0.840	2012	Psychoactive substance	Availability and use of NPS
2	49	0.809	2014	Acute recreational drug toxicity	Neuropharmacology of NPS
3	34	0.820	2016	Strida project	Intoxication profile and detection of NPS use
4	26	0.994	2020	New synthetic opioid	New synthetic opioids
5	18	0.992	2012	Legal consequence	Legal aspects of NPS use
6	13	0.928	2017	Synthetic cannabinoid	Synthetic cannabinoids
8	8	0.984	2014	Rat urine	Metabolite profiles for drug screening
9	6	1.00	2013	Mapping project	NPS and the Internet
10	6	0.967	2015	Emerging epidemic	NPS as a New Public Health Problem



## 154 4. Discussion

155 In this section, we will discuss each cluster in greater detail in chrono-  
156 logical order, by the average year of publication of the cluster. Each cluster  
157 will be analysed in terms of both the citing articles and the cited references.  
158 The main citing articles for each cluster will be highlighted, together with  
159 its coverage and Global Citing Score (GCS). Coverage refers to the number  
160 of articles in the cluster that were cited by the citing article and GCS refers  
161 to the total number of citations received by a paper as indexed on Scopus.

### 162 4.1. Cluster #5: Legal aspects of NPS

163 The major citing articles in Cluster #5 were authored by Bilinski et al.  
164 [46] with a coverage of 14 articles and GCS of 6, and B McNabb et al. [47]  
165 with a coverage of 11 articles and GCS of 11. Cluster #5 appears to be  
166 one of the earlier groups of work investigating NPS emerging on the drug  
167 market, their effects and their legal status, as seen from the mean year of  
168 publication (2012) and a significant number of cited references conducted in  
169 animal models prior to 2010 [48, 49, 50, 51, 52]. The primary theme of this  
170 cluster appears to be legal concerns of NPS use following their entrance into  
171 the market, where the citing articles focused on the legality of designer drugs  
172 touted as “legal” in the drug market [46, 47]. Accordingly, there were also  
173 cited references looking into the legal aspects of NPS use [53, 54].

### 174 4.2. Cluster #1: Availability and use of NPS

175 The major citing articles in Cluster #1 were authored by Smith and  
176 Garlich [55] with a coverage of 21 articles and GCS of 14, Wood and Dargan  
177 [56] with a coverage of 16 articles and GCS of 7, and Wood and Dargan [57]  
178 with a coverage of 14 articles and GCS of 54. Cluster #1 appears to be a  
179 body of work that emerged in response to the series of bans on mephedrone  
180 as well as other cathinones across multiple countries across the world in  
181 2010, as evidenced by the mean year of publication (2012). The focus of  
182 both citing articles and the cited references appeared to be the same, which  
183 primarily revolved about the effects, prevalence and use of mephedrone and  
184 other cathinones. A significant number of cited references examined their  
185 use [38, 58, 59] and continued presence in the composition of existing drug  
186 products available in the market [60, 35] despite their legal status, as well  
187 as their effects (e.g. [61, 59, 62, 63]). This was also the case for many of  
188 the citing articles which also looked at the effects of mephedrone and other  
189 cathinones [57, 64, 56, 65].



### 190 4.3. Cluster #9: NPS and the Internet

191 The major citing articles in Cluster #9 were authored by Deluca et al. [66]  
 192 with a coverage of 3 articles and GCS of 139, Cinosi et al. [67] with a coverage  
 193 of 2 articles and GCS of 99, and Corazza et al. [68] with a coverage of 2 articles  
 194 and GCS of 52. The main theme of Cluster #9 is the role of the Internet as  
 195 a source for information on NPS as well as a virtual marketplace for NPS.  
 196 It is clear from the cited articles that the availability of NPS through online  
 197 channels is a key concern, especially since consumer reach and engagement  
 198 on the Internet is unrivalled in comparison to a brick-and-mortar store, as  
 199 well as the information on NPS available on the Internet (e.g. [69, 70, 71,  
 200 72]). Targeting the Internet through researching and designing web-based  
 201 interventions such as web monitoring and information dissemination is thus  
 202 a recommendation and/or central focus of the citing articles in Cluster #9  
 203 (e.g. [66, 68]). Research in Cluster #9 highlights the information war on the  
 204 Internet as a key aspect of the NPS crisis and the importance of developing  
 205 information and communication technology interventions.

### 206 4.4. Cluster #8: Metabolite profiles for drug screening

207 The two major citing articles in Cluster #8 were authored by Welter et al.  
 208 [73] with a coverage of 8 articles and GCS of 25 and Welter et al. [74] with a  
 209 coverage of 72 articles and GCS of 6. Both of these citing articles investigated  
 210 methods for detecting of designer drugs through screening the metabolic  
 211 products present in rat urine by applying gas chromatography-mass spec-  
 212 troscopy and/or liquid chromatography methods. This strongly suggests the  
 213 cluster is geared towards the application of these chemical methods to NPS  
 214 detection. Majority of the cited articles also report the results of applying  
 215 these methods to detect drug metabolites in urine (e.g. [75, 76, 77, 78, 79]).

### 216 4.5. Cluster #2: Neuropsychopharmacology of NPS

217 The major citing articles in Cluster #2 were authored by Zawilska and  
 218 Andrzejczak [80] with a coverage of 10 articles and GCS of 120, Papaseit et al.  
 219 [81] with a coverage of 10 articles and GCS of 20, and [82] with a coverage  
 220 of 10 articles and GCS of 88, which were all reviews on the pharmacology  
 221 of NPS use. The cluster is centred in elucidating the pharmacology of the  
 222 various classes of NPS, which the citing articles covered from cathinones  
 223 (e.g. [83, 84]), cannabinoids (e.g. [85]), hallucinogens [86] and stimulants  
 224 [87]. The same theme is reflected in the cited articles, which were mostly  
 225 concerned with the toxicological findings from NPS use [33, 88, 43, 89, 90].

Hence, Cluster #2 appears to be a body of work relating pharmacological properties of NPS to their toxicity and risk of fatality.

#### 4.6. Cluster #10: NPS as a New Public Health Problem

The major citing articles in Cluster #10 were authored by Zawilska and Andrzejczak [80] with a coverage of 4 articles and GCS of 36, Karila et al. [91] with a coverage of 3 articles and GCS of 129, and Rickli et al. [36] with a coverage of 3 articles and GCS of 129. The focus of these reviews aims to consolidate information on properties of NPS in relation to their propensity as a public health threat by presenting clinical data. The findings in the cited references also presents clinical data [92], including psychosis [93].

#### 4.7. Cluster #3: Intoxication profile of NPS use

The major citing articles in Cluster #3 were authored by Schifano et al. [94] with a coverage of 7 articles and GCS of 178, Salomone [95] with a coverage of 7 articles and GCS of 85, and Castaneto et al. [96] with a coverage of 7 articles and GCS of 4, which were all reviews on the pharmacology of NPS use. The cluster is composed of a group of work collecting data on the intoxication profiles of NPS users (e.g. [97, 98, 99, 100, 101]). Notably, a significant number of the citing articles analysed data from the STRIDA project in Sweden, which monitored occurrences and health hazards of NPS and includes information from about 2,600 cases of suspected NPS intoxications across the period of 2010-2016 [102, 103, 104, 105, 106, 107]. Similarly, the cited references were also research on intoxication profiles and fatality from NPS use (e.g. [108, 109, 110, 111, 112, 113, 114, 115]). The size of the cluster alludes to the public health threat that NPS use poses, as well as the importance of the field of emergency medicine in monitoring adverse events relating to drug use which can provide much needed data on the toxicological and risk profile of NPS use.

#### 4.8. Cluster #6: Synthetic cannabinoids

The major citing articles in Cluster #6 were authored by Cannaert et al. [116] with a coverage of 5 articles and GCS of 22, Ametovski et al. [117] with a coverage of 5 articles and GCS of 5, and [118] with a coverage of 4 articles and GCS of 18. Considering that marijuana - which contains cannabis - is one of the most commonly use drugs in the world [119], it is not surprising that synthetic cannabinoids gained popularity as a “legal” alternative in countries - “Spice” being an example of a brand name cannabinoid drug

- where cannabis is controlled. Hence, this cluster of work examining the effects of the recreational use of these synthetic cannabinoids appears to be in response to their widespread use and market penetration in the recreational drug market, especially considering its mean year of publication in 2017, which was around the time period when cannabis began to be legalised for recreational use and sale as a consumer product across a number of countries such as Canada and the USA. The citing articles include research into the pharmacology [120, 121, 122, 123], toxicology [124, 125, 126, 127] as well as a number of articles pointing towards the sheer volume and continued emergence of variations of synthetic cannabinoids [118, 128, 129]. Similarly, a bulk of the cited references also focus mainly on synthetic cannabinoids and their fatalities associated with their use [32, 130, 131, 132].

#### 4.9. Cluster #0: Mechanisms of NPS action

The major citing articles in Cluster #0 were authored by Miliano et al. [82] with a coverage of 13 articles and GCS of 88, Rudin et al. [133] with a coverage of 12 articles and GCS of 9, and Ellefsen et al. [83] with a coverage of 11 articles and GCS of 45, which were all reviews on the pharmacological effects of NPS use. Firstly, many of the cited references in the cluster discussed fatalities from NPS use (e.g. [31, 39, 134, 135]), indicating that research on NPS is driven towards characterising the risk profile of NPS use in terms of clinical outcomes and fatalities. Secondly, each of the major citing articles were focused on different classes of NPS; Miliano et al. [82] focused on cannabimimetics and amphetamine stimulants, Rudin et al. [133] on stimulant and psychedelic NPS and Ellefsen et al. [83] on synthetic cathinones. This highlights the diversity of NPS classes available, which poses an immense challenge to the scientific community as evidenced by the constant refrain of a lack of understanding of these mechanisms in many citing articles. A tremendous effort is required in organising and conducting research into understanding the drug action and effects of the different classes of NPS, as seen from the size of this cluster. A defining characteristic of the NPS phenomenon, the rapid development of NPS entering the drug market suggests the continual need for research to update the scientific understanding of the mechanisms of drug action, which is suggested by the relatively recent mean year of publication (2019). Many of the references being cited were also investigating the pharmacological actions and toxicity of NPS (e.g. [36, 41, 136, 137, 138, 139]), further highlighting the need to constantly build

297 onto existing scientific knowledge because of the sheer speed of NPS varia-  
298 tions being introduced in the market.

#### 299 *4.10. Cluster #4: New synthetic opioids*

300 The major citing articles in Cluster #4 were authored by Vandeputte  
301 et al. [140] with a coverage of 7 articles and GCS of 1, Vandeputte et al.  
302 [141] with a coverage of 7 articles and GCS of 3, and [142] with a coverage of  
303 7 articles and GCS of 10. Given its recent mean year of publication (2020),  
304 the cluster is very likely to be a group of work in response to rising use of  
305 synthetic opioids globally. While the opioid crisis is not a new phenomenon, a  
306 spotlight has been thrown onto synthetic opioid use in the wake of the recent  
307 surge in opioid overdose deaths in the US - an opioid overdose epidemic driven  
308 by synthetic opioids, fentanyl and its derivatives in particular [143, 144, 145].  
309 The cited reference with the highest burst strengths in this cluster focuses  
310 on fentanyl and other novel synthetic opioids [34, 146, 147], supporting this  
311 notion. Many citing articles were concerned with opioid-related deaths [39,  
312 148, 149, 150] and a significant number of articles pointed towards the rapidly  
313 surging numbers globally and its implications on public health [151, 152, 153].

#### 314 *4.11. Limitations*

315 There are a number of limitations of the scientometric approach. The  
316 DCA is based on the quantity of citations and co-citation patterns in the  
317 retrieved references and does not provide a qualitative perspective for these  
318 citation patterns per se. Hence, the rationale for the cited references are not  
319 immediately clear from the scientometric analysis.

## 320 **5. Conclusions**

321 The NPS phenomenon is a major cause for concern in countries across  
322 the globe and is a war on drugs fought on many fronts, as evidenced by the  
323 diversity of scientific fields represented in the network of articles derived from  
324 the DCA. Given the challenges that NPS pose in terms of drug monitoring,  
325 surveillance, control and public health responses, understanding the scientific  
326 literature and disciplines involved in research on NPS is a valuable contribu-  
327 tion to the field which can be harnessed in supporting drug policy and public  
328 health response. Such an analysis can highlight the research gaps in NPS  
329 to direct attention to and facilitating interdisciplinary research based on the  
330 research domains and links identified. In addition, producers of NPS often

mine knowledge from scientific journals and an understanding of the information that is available can be useful in targeting and informing drug policy. Thus, drug policy, monitoring and control can benefit from coordinated, interdisciplinary efforts to inform and develop a multi-pronged approach to the NPS crisis in order to safeguard public health.

## Conflict of interests

The authors declare no conflict of interest.

## References

- [1] U. N. O. on Drugs, Crime, Unodc early warning advisory on new psychoactive substances, 2021. URL: <https://www.unodc.org/LSS/Page/NPS>.
- [2] C. Soussan, A. Kjellgren, The users of novel psychoactive substances: online survey about their characteristics, attitudes and motivations, *International Journal of Drug Policy* 32 (2016) 77–84.
- [3] A. Batisse, C. Eiden, H. Peyriere, S. Djeddar, et al., Use of new psychoactive substances to mimic prescription drugs: The trend in france, *Neurotoxicology* 79 (2020) 20–24.
- [4] C. D. Smith, S. Robert, ‘designer drugs’: update on the management of novel psychoactive substance misuse in the acute care setting, *Clinical medicine* 14 (2014) 409.
- [5] C. D. Smith, M. Williams, M. Shaikh, Novel psychoactive substances: a novel clinical challenge, *Case Reports* 2013 (2013) bcr2013200663.
- [6] N. Scherbaum, F. Schifano, U. Bonnet, New psychoactive substances (nps)—a challenge for the addiction treatment services, *Pharmacopsychiatry* 50 (2017) 116–122.
- [7] P. O. of the European Union, M. Evans-Brown, A. Gallegos, W. Francis, R. Christie, A. Cunningham, J. Sekula, A. Almeida, R. Sedefov, Publications Office, 2015.
- [8] M. Evans-Brown, R. Sedefov, New psychoactive substances: driving greater complexity into the drug problem, *Addiction* 112 (2017) 36–38.

- 361 [9] A. Peacock, R. Bruno, N. Gisev, L. Degenhardt, W. Hall, R. Sedefov,  
362 J. White, K. V. Thomas, M. Farrell, P. Griffiths, New psychoactive  
363 substances: challenges for drug surveillance, control, and public health  
364 responses, *The Lancet* 394 (2019) 1668–1684.
- 365 [10] L. Kraus, A. Nociar, ESPAD report 2015: results from the European  
366 school survey project on alcohol and other drugs, European Monitoring  
367 Centre for Drugs and Drug Addiction, 2016.
- 368 [11] C. Chen, The citespace manual, College of Computing and Informatics  
369 1 (2014) 1–84.
- 370 [12] C. Chen, F. Ibekwe-SanJuan, J. Hou, The structure and dynamics of  
371 cocitation clusters: A multiple-perspective cocitation analysis, *Journal*  
372 *of the American Society for information Science and Technology* 61  
373 (2010) 1386–1409.
- 374 [13] A. Carollo, J. P. M. Balagtas, M. J.-Y. Neoh, G. Esposito, A sciento-  
375 metric approach to review the role of the medial preoptic area (mpoa)  
376 in parental behavior, *Brain Sciences* 11 (2021) 393.
- 377 [14] I. Cataldo, A. A. Lieu, A. Carollo, M. H. Bornstein, G. Gabrieli, A. Lee,  
378 G. Esposito, From the cradle to the web: The growth of “sharent-  
379 ing”—a scientometric perspective, *Human Behavior and Emerging*  
380 *Technologies* 2022 (2022).
- 381 [15] A. Carollo, A. Bonassi, M. Lim, G. Gabrieli, P. Setoh, D. Dimitriou,  
382 V. Aryadoust, G. Esposito, Developmental disabilities across the world:  
383 A scientometric review from 1936 to 2020, *Research in Developmental*  
384 *Disabilities* 117 (2021) 104031.
- 385 [16] C. Chen, CiteSpace: a practical guide for mapping scientific literature,  
386 Nova Science Publishers Hauppauge, NY, USA, 2016.
- 387 [17] H. Small, Co-citation context analysis and the structure of paradigms,  
388 *Journal of documentation* (1980).
- 389 [18] A. Carollo, M. Lim, V. Aryadoust, G. Esposito, Interpersonal syn-  
390 chrony in the context of caregiver-child interactions: a document co-  
391 citation analysis, *Frontiers in Psychology* (2021) 2977.

- 392 [19] A. Carollo, S. Fong, G. Gabrieli, C. Mulatti, G. Esposito, To wine or  
393 not to wine? a scientometric approach to 65+ years of wine preference  
394 and selection studies, *British Food Journal* (2022).
- 395 [20] M. Lim, A. Carollo, D. Dimitriou, G. Esposito, Recent developments  
396 in autism genetic research: A scientometric review from 2018 to 2022,  
397 *Genes* 13 (2022) 1646.
- 398 [21] L. Egghe, Theory and practise of the g-index, *Scientometrics* 69 (2006)  
399 131–152.
- 400 [22] S. Alonso, F. J. Cabrerizo, E. Herrera-Viedma, F. Herrera, h-index:  
401 A review focused in its variants, computation and standardization for  
402 different scientific fields, *Journal of informetrics* 3 (2009) 273–289.
- 403 [23] M. E. Newman, Modularity and community structure in networks,  
404 *Proceedings of the national academy of sciences* 103 (2006) 8577–8582.
- 405 [24] P. J. Rousseeuw, Silhouettes: a graphical aid to the interpretation and  
406 validation of cluster analysis, *Journal of computational and applied*  
407 *mathematics* 20 (1987) 53–65.
- 408 [25] V. Aryadoust, B. H. Ang, Exploring the frontiers of eye tracking re-  
409 search in language studies: a novel co-citation scientometric review,  
410 *Computer Assisted Language Learning* 34 (2021) 898–933.
- 411 [26] L. C. Freeman, A set of measures of centrality based on betweenness,  
412 *Sociometry* (1977) 35–41.
- 413 [27] V. Aryadoust, H. A. H. Tan, L. Y. Ng, A scientometric review of  
414 rasch measurement: The rise and progress of a specialty, *Frontiers in*  
415 *psychology* (2019) 2197.
- 416 [28] J. Kleinberg, Bursty and hierarchical structure in streams, *Data mining*  
417 *and knowledge discovery* 7 (2003) 373–397.
- 418 [29] C. Chen, Science mapping: a systematic review of the literature, *Jour-*  
419 *nal of data and information science* 2 (2017) 1–40.
- 420 [30] C. Chen, Y. Chen, M. Horowitz, H. Hou, Z. Liu, D. Pellegrino, To-  
421 wards an explanatory and computational theory of scientific discovery,  
422 *Journal of Informetrics* 3 (2009) 191–209.



- 423 [31] L. Hondebrink, J. J. Nugteren-van Lonkhuyzen, D. Van Der Gouwe,  
424 T. M. Brunt, Monitoring new psychoactive substances (nps) in the  
425 netherlands: data from the drug market and the poisons information  
426 centre, *Drug and alcohol dependence* 147 (2015) 109–115.
- 427 [32] M. S. Castaneto, D. A. Gorelick, N. A. Desrosiers, R. L. Hartman,  
428 S. Pirard, M. A. Huestis, Synthetic cannabinoids: epidemiology, phar-  
429 macodynamics, and clinical implications, *Drug and alcohol dependence*  
430 144 (2014) 12–41.
- 431 [33] M. Hermanns-Clausen, S. Kneisel, B. Szabo, V. Auwärter, Acute toxi-  
432 city due to the confirmed consumption of synthetic cannabinoids: clin-  
433 ical and laboratory findings, *Addiction* 108 (2013) 534–544.
- 434 [34] P. Armenian, K. T. Vo, J. Barr-Walker, K. L. Lynch, Fentanyl, fen-  
435 tanyl analogs and novel synthetic opioids: a comprehensive review,  
436 *Neuropharmacology* 134 (2018) 121–132.
- 437 [35] S. D. Brandt, L. A. King, M. Evans-Brown, The new drug phenomenon,  
438 2014.
- 439 [36] A. Rickli, M. C. Hoener, M. E. Liechti, Monoamine transporter and  
440 receptor interaction profiles of novel psychoactive substances: para-  
441 halogenated amphetamines and pyrovalerone cathinones, *European*  
442 *Neuropsychopharmacology* 25 (2015) 365–376.
- 443 [37] H. Morris, J. Wallach, From pcp to mxe: a comprehensive review of  
444 the non-medical use of dissociative drugs, *Drug testing and analysis* 6  
445 (2014) 614–632.
- 446 [38] F. Measham, D. M. Wood, P. I. Dargan, K. Moore, The rise in legal  
447 highs: prevalence and patterns in the use of illegal drugs and first-  
448 and second-generation “legal highs” in south london gay dance clubs,  
449 *Journal of Substance Use* 16 (2011) 263–272.
- 450 [39] M. Kraemer, A. Boehmer, B. Madea, A. Maas, Death cases involv-  
451 ing certain new psychoactive substances: a review of the literature,  
452 *Forensic science international* 298 (2019) 186–267.

- 453 [40] K. A. Seely, J. Lapoint, J. H. Moran, L. Fattore, Spice drugs are more  
454 than harmless herbal blends: a review of the pharmacology and toxicol-  
455 ogy of synthetic cannabinoids, *Progress in Neuro-psychopharmacology*  
456 and biological psychiatry 39 (2012) 234–243.
- 457 [41] L. H. Richter, H. H. Maurer, M. R. Meyer, New psychoactive sub-  
458 stances: studies on the metabolism of xlr-11, ab-pinaca, fub-pb-22,  
459 4-methoxy- $\alpha$ -pvp, 25-i-nbome, and meclonazepam using human liver  
460 preparations in comparison to primary human hepatocytes, and hu-  
461 man urine, *Toxicology Letters* 280 (2017) 142–150.
- 462 [42] M. H. Baumann, M. A. Ayestas, J. S. Partilla, J. R. Sink, A. T.  
463 Shulgin, P. F. Daley, S. D. Brandt, R. B. Rothman, A. E. Ruoho,  
464 N. V. Cozzi, The designer methcathinone analogs, mephedrone and  
465 methylone, are substrates for monoamine transporters in brain tissue,  
466 *Neuropsychopharmacology* 37 (2012) 1192–1203.
- 467 [43] J. M. Prosser, L. S. Nelson, The toxicology of bath salts: a review of  
468 synthetic cathinones, *Journal of Medical Toxicology* 8 (2012) 33–42.
- 469 [44] M. Majchrzak, R. Celiński, P. Kuś, T. Kowalska, M. Sajewicz, The  
470 newest cathinone derivatives as designer drugs: an analytical and tox-  
471 icological review, *Forensic toxicology* 36 (2018) 33–50.
- 472 [45] D. Favretto, J. P. Pascali, F. Tagliaro, New challenges and innovation  
473 in forensic toxicology: focus on the “new psychoactive substances”,  
474 *Journal of chromatography A* 1287 (2013) 84–95.
- 475 [46] P. Bilinski, P. Holownia, L. Kapka-Skrzypczak, A. Wojtyła, Designer  
476 drug (dd) abuse in poland; a review of the psychoactive and toxic prop-  
477 erties of substances found from seizures of illegal drug products and the  
478 legal consequences thereof. part ii–piperazines/piperidines, phenylethy-  
479 lamines, tryptamines and miscellaneous ‘others’, *Annals of Agricultural*  
480 *and Environmental Medicine* 19 (2012).
- 481 [47] C. B McNabb, B. R Russell, D. Caprioli, D. J Nutt, S. Gibbons,  
482 J. W Dalley, Single chemical entity legal highs: assessing the risk  
483 for long term harm, *Current Drug Abuse Reviews* 5 (2012) 304–319.

- 484 [48] R. Nonaka, F. Nagai, A. Ogata, K. Satoh, In vitro screening of psy-  
485 choactive drugs by [35s] gtpγs binding in rat brain membranes, Bio-  
486 logical and Pharmaceutical Bulletin 30 (2007) 2328–2333.
- 487 [49] F. Nagai, R. Nonaka, K. S. H. Kamimura, The effects of non-medically  
488 used psychoactive drugs on monoamine neurotransmission in rat brain,  
489 European journal of pharmacology 559 (2007) 132–137.
- 490 [50] W. E. Fantegrossi, G. Winger, J. Woods, W. Woolverton, A. Coop, Re-  
491 inforcing and discriminative stimulus effects of 1-benzylpiperazine and  
492 trifluoromethylphenylpiperazine in rhesus monkeys, Drug and alcohol  
493 dependence 77 (2005) 161–168.
- 494 [51] K. M. Wilcox, H. L. Kimmel, K. P. Lindsey, J. R. Votaw, M. M. Good-  
495 man, L. L. Howell, In vivo comparison of the reinforcing and dopamine  
496 transporter effects of local anesthetics in rhesus monkeys, Synapse 58  
497 (2005) 220–228.
- 498 [52] M. H. Baumann, R. D. Clark, A. G. Budzynski, J. S. Partilla, B. E.  
499 Blough, R. B. Rothman, Effects of “legal x” piperazine analogs on  
500 dopamine and serotonin release in rat brain, Annals of the New York  
501 Academy of Sciences 1025 (2004) 189–197.
- 502 [53] S. Davies, D. M. Wood, G. Smith, J. Button, J. Ramsey, R. Archer,  
503 D. W. Holt, P. I. Dargan, Purchasing ‘legal highs’ on the internet—is  
504 there consistency in what you get?, QJM: An International Journal of  
505 Medicine 103 (2010) 489–493.
- 506 [54] L. Kapka-Skrzypczak, P. Kulpa, K. Sawicki, M. Cyranka, A. Wojtyła,  
507 M. Kruszewski, Legal highs-legal aspects and legislative solutions, An-  
508 nals of Agricultural and Environmental Medicine 18 (2011).
- 509 [55] S. W. Smith, F. M. Garlich, Availability and supply of novel psychoac-  
510 tive substances, in: Novel psychoactive substances, Elsevier, 2013, pp.  
511 55–77.
- 512 [56] D. M. Wood, P. I. Dargan, Mephedrone, in: Novel psychoactive sub-  
513 stances, Elsevier, 2013, pp. 211–231.

- 514 [57] D. M. Wood, P. I. Dargan, Novel psychoactive substances: how to un-  
515 derstand the acute toxicity associated with the use of these substances,  
516 Therapeutic drug monitoring 34 (2012) 363–367.
- 517 [58] D. Wood, L. Hunter, F. Measham, P. Dargan, Limited use of novel  
518 psychoactive substances in south london nightclubs, QJM: An inter-  
519 national journal of medicine 105 (2012) 959–964.
- 520 [59] P. Dargan, S. Albert, D. Wood, Mephedrone use and associated ad-  
521 verse effects in school and college/university students before the uk  
522 legislation change, QJM: An International Journal of Medicine 103  
523 (2010) 875–879.
- 524 [60] J. Ramsey, P. Dargan, M. Smyllie, S. Davies, J. Button, D. Holt,  
525 D. Wood, Buying ‘legal’ recreational drugs does not mean that you  
526 are not breaking the law, QJM: An International Journal of Medicine  
527 103 (2010) 777–783.
- 528 [61] D. M. Wood, S. Davies, M. Puchnarewicz, J. Button, R. Archer,  
529 H. Ovaska, J. Ramsey, T. Lee, D. W. Holt, P. I. Dargan, Recreational  
530 use of mephedrone (4-methylmethcathinone, 4-mmC) with associated  
531 sympathomimetic toxicity, Journal of Medical Toxicology 6 (2010)  
532 327–330.
- 533 [62] D. Wood, S. Greene, P. Dargan, Clinical pattern of toxicity associated  
534 with the novel synthetic cathinone mephedrone, Emergency medicine  
535 journal 28 (2011) 280–282.
- 536 [63] P. I. Dargan, R. Sedefov, A. Gallegos, D. M. Wood, The phar-  
537 macology and toxicology of the synthetic cathinone mephedrone (4-  
538 methylmethcathinone), Drug testing and analysis 3 (2011) 454–463.
- 539 [64] D. Wood, P. Dargan, Understanding how data triangulation identifies  
540 acute toxicity of novel psychoactive drugs, Journal of Medical Toxicol-  
541 ogy 8 (2012) 300–303.
- 542 [65] B. Loi, J. M. Corkery, H. Claridge, C. Goodair, S. Chiappini, C. Gi-  
543 meno Clemente, F. Schifano, Deaths of individuals aged 16–24 years in  
544 the uk after using mephedrone, Human Psychopharmacology: Clinical  
545 and Experimental 30 (2015) 225–232.

- 546 [66] P. Deluca, Z. Davey, O. Corazza, L. Di Furia, M. Farre, L. H. Flesland,  
547 M. Mannonen, A. Majava, T. Peltoniemi, M. Pasinetti, et al., Identifying emerging trends in recreational drug use; outcomes from the psychonaut web mapping project, *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 39 (2012) 221–226.
- 551 [67] E. Cinosi, G. Martinotti, P. Simonato, D. Singh, Z. Demetrovics,  
552 A. Roman-Urrestarazu, F. S. Bersani, B. Vicknasingam, G. Piazzon,  
553 J.-H. Li, et al., Following “the roots” of kratom (*mitragyna speciosa*):  
554 the evolution of an enhancer from a traditional use to increase work  
555 and productivity in southeast asia to a recreational psychoactive drug  
556 in western countries, *BioMed research international* 2015 (2015).
- 557 [68] O. Corazza, G. Valeriani, F. S. Bersani, J. Corkery, G. Martinotti,  
558 G. Bersani, F. Schifano, “spice,” “kryptonite,” “black mamba”: an  
559 overview of brand names and marketing strategies of novel psychoactive  
560 substances on the web, *Journal of Psychoactive Drugs* 46 (2014)  
561 287–294.
- 562 [69] O. Corazza, S. Assi, P. Simonato, J. Corkery, F. S. Bersani, Z. Demetrovics,  
563 J. Stair, S. Fergus, C. Pezzolesi, M. Pasinetti, et al., Promoting  
564 innovation and excellence to face the rapid diffusion of novel psychoactive  
565 substances in the eu: the outcomes of the rednet project, *Human Psychopharmacology: Clinical and Experimental* 28 (2013) 317–323.
- 567 [70] F. Schifano, O. Corazza, P. Deluca, Z. Davey, L. Di Furia, M. Farre’,  
568 L. Flesland, M. Mannonen, S. Pagani, T. Peltoniemi, et al., Psychoactive drug or mystical incense? overview of the online available  
569 information on spice products, *International Journal of Culture and Mental Health* 2 (2009) 137–144.
- 572 [71] O. Corazza, F. Schifano, P. Simonato, S. Fergus, S. Assi, J. Stair,  
573 J. Corkery, G. Trincas, P. Deluca, Z. Davey, et al., Phenomenon of  
574 new drugs on the internet: the case of ketamine derivative methoxetamine,  
575 *Human Psychopharmacology: Clinical and Experimental* 27  
576 (2012) 145–149.
- 577 [72] F. Schifano, P. Deluca, L. Agosti, G. Martinotti, J. M. Corkery, P. . R.  
578 Group, New trends in the cyber and street market of recreational

- 579 drugs? the case of 2c-t-7 ('blue mystic'), *Journal of Psychopharmacol-*  
580 *ogy* 19 (2005) 675–679.
- 581 [73] J. Welter, M. R. Meyer, P. Kavanagh, H. H. Maurer, Studies on the  
582 metabolism and the detectability of 4-methyl-amphetamine and its iso-  
583 mers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine  
584 using gc-ms and lc-(high-resolution)-ms n, *Analytical and bioanalyti-*  
585 *cal chemistry* 406 (2014) 1957–1974.
- 586 [74] J. Welter, P. Kavanagh, H. H. Maurer, Gc-ms and lc-(high-resolution)-  
587 ms n studies on the metabolic fate and detectability of camfetamine  
588 in rat urine, *Analytical and bioanalytical chemistry* 406 (2014) 3815–  
589 3829.
- 590 [75] M. R. Meyer, F. T. Peters, H. H. Maurer, Automated mass spectral  
591 deconvolution and identification system for gc-ms screening for drugs,  
592 poisons, and metabolites in urine, *Clinical chemistry* 56 (2010) 575–  
593 584.
- 594 [76] A. H. Ewald, D. Ehlers, H. H. Maurer, Metabolism and toxicological  
595 detection of the designer drug 4-chloro-2, 5-dimethoxyamphetamine in  
596 rat urine using gas chromatography-mass spectrometry, *Analytical and*  
597 *bioanalytical chemistry* 390 (2008) 1837–1842.
- 598 [77] M. R. Meyer, M. Bach, J. Welter, M. Bovens, A. Turcant, H. H. Maurer,  
599 Ketamine-derived designer drug methoxetamine: metabolism including  
600 isoenzyme kinetics and toxicological detectability using gc-ms and lc-  
601 (hr-) ms n, *Analytical and bioanalytical chemistry* 405 (2013) 6307–  
602 6321.
- 603 [78] D. K. Wissenbach, M. R. Meyer, D. Remane, A. A. Weber, H. H.  
604 Maurer, Development of the first metabolite-based lc-ms n urine drug  
605 screening procedure-exemplified for antidepressants, *Analytical and*  
606 *bioanalytical chemistry* 400 (2011) 79–88.
- 607 [79] D. K. Wissenbach, M. R. Meyer, D. Remane, A. A. Philipp, A. A.  
608 Weber, H. H. Maurer, Drugs of abuse screening in urine as part of a  
609 metabolite-based lc-msn screening concept, *Analytical and Bioanalyti-*  
610 *cal Chemistry* 400 (2011) 3481–3489.

- 611 [80] J. B. Zawilska, D. Andrzejczak, Next generation of novel psychoac-  
612 tive substances on the horizon—a complex problem to face, *Drug and*  
613 *Alcohol Dependence* 157 (2015) 1–17.
- 614 [81] E. Papaseit, J. Moltó, R. Muga, M. Torrens, R. d. l. Torre, M. Farré,  
615 Clinical pharmacology of the synthetic cathinone mephedrone, *Neu-*  
616 *ropharmacology of New Psychoactive Substances (NPS)* (2016) 313–  
617 331.
- 618 [82] C. Miliano, G. Serpelloni, C. Rimondo, M. Mereu, M. Marti, M. A.  
619 De Luca, Neuropharmacology of new psychoactive substances (nps):  
620 focus on the rewarding and reinforcing properties of cannabimimetics  
621 and amphetamine-like stimulants, *Frontiers in neuroscience* 10 (2016)  
622 153.
- 623 [83] K. N. Ellefsen, M. Concheiro, M. A. Huestis, Synthetic cathinone  
624 pharmacokinetics, analytical methods, and toxicological findings from  
625 human performance and postmortem cases, *Drug metabolism reviews*  
626 48 (2016) 237–265.
- 627 [84] E. Papaseit, C. Pérez-Mañá, J.-A. Mateus, M. Pujadas, F. Fonseca,  
628 M. Torrens, E. Olesti, R. De La Torre, M. Farré, Human pharmacology  
629 of mephedrone in comparison with mdma, *Neuropsychopharmacology*  
630 41 (2016) 2704–2713.
- 631 [85] C. Lovett, D. Wood, P. Dargan, Pharmacology and toxicology of the  
632 synthetic cannabinoid receptor agonists, *Réanimation* 24 (2015) 527–  
633 541.
- 634 [86] C. Kyriakou, E. Marinelli, P. Frati, A. Santurro, M. Afxentiou, S. Za-  
635 ami, F. P. Busardo, Nbome: new potent hallucinogens—pharmacology,  
636 analytical methods, toxicities, fatalities: a review, *Eur Rev Med Phar-*  
637 *macol Sci* 19 (2015) 3270–3281.
- 638 [87] J. J. Nugteren-van Lonkhuyzen, A. J. van Riel, T. M. Brunt, L. Hon-  
639 debrink, Pharmacokinetics, pharmacodynamics and toxicology of new  
640 psychoactive substances (nps): 2c-b, 4-fluoroamphetamine and benzo-  
641 furans, *Drug and alcohol dependence* 157 (2015) 18–27.



- [88] M. Coppola, R. Mondola, 3, 4-methylenedioxypyrovalerone (mdpv): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online, *Toxicology Letters* 208 (2012) 12–15.
- [89] S. L. Hill, T. Doris, S. Gurung, S. Katebe, A. Lomas, M. Dunn, P. Blain, S. H. Thomas, Severe clinical toxicity associated with analytically confirmed recreational use of 25i-nbome: case series, *Clinical Toxicology* 51 (2013) 487–492.
- [90] D. James, R. D. Adams, R. Spears, G. Cooper, D. Lupton, J. P. Thompson, S. H. Thomas, Clinical characteristics of mephedrone toxicity reported to the uk national poisons information service, *Emergency Medicine Journal* 28 (2011) 686–689.
- [91] L. Karila, B. Megarbane, O. Cottencin, M. Lejoyeux, Synthetic cathinones: a new public health problem, *Current neuropharmacology* 13 (2015) 12–20.
- [92] H. A. Spiller, M. L. Ryan, R. G. Weston, J. Jansen, Clinical experience with and analytical confirmation of “bath salts” and “legal highs”(synthetic cathinones) in the united states, *Clinical toxicology* 49 (2011) 499–505.
- [93] D. Papanti, F. Schifano, G. Botteon, F. Bertossi, J. Mannix, D. Vidoni, M. Impagnatiello, E. Pascolo-Fabrizi, T. Bonavigo, “spiceophrenia”: a systematic overview of “spice”-related psychopathological issues and a case report, *Human Psychopharmacology: Clinical and Experimental* 28 (2013) 379–389.
- [94] F. Schifano, L. Orsolini, G. Duccio Papanti, J. M. Corkery, Novel psychoactive substances of interest for psychiatry, *World Psychiatry* 14 (2015) 15–26.
- [95] A. Salomone, Detection of new psychoactive substances, in: *Hair Analysis in Clinical and Forensic Toxicology*, Elsevier, 2015, pp. 301–336.
- [96] M. S. Castaneto, A. Wohlfarth, N. A. Desrosiers, R. L. Hartman, D. A. Gorelick, M. A. Huestis, Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices, *Drug metabolism reviews* 47 (2015) 124–174.

- 675 [97] R. Kronstrand, D. Guerrieri, S. Vikingsson, A. Wohlfarth, H. Gr  en,  
676 Fatal poisonings associated with new psychoactive substances, in: New  
677 psychoactive substances, Springer, 2018, pp. 495–541.
- 678 [98] S. L. Hill, P. I. Dargan, Patterns of acute toxicity associated with new  
679 psychoactive substances, in: New Psychoactive Substances, Springer,  
680 2018, pp. 475–494.
- 681 [99] L. Ventura, F. Carvalho, R. J. Dinis-Oliveira, Opioids in the frame of  
682 new psychoactive substances network: a complex pharmacological and  
683 toxicological issue, Current Molecular Pharmacology 11 (2018) 97–108.
- 684 [100] M. H. Tang, Y. Chong, C. Y. Chan, C. Ching, C. Lai, Y. Li, T. W.  
685 Mak, Cluster of acute poisonings associated with an emerging ketamine  
686 analogue, 2-oxo-pce, Forensic science international 290 (2018) 238–243.
- 687 [101] C. R. Caffrey, P. M. Lank, When good times go bad: managing ‘legal  
688 high’ complications in the emergency department, Open access emer-  
689 gency medicine: OAEM 10 (2018) 9.
- 690 [102] M. B  ckberg, O. Beck, A. Helander, Phencyclidine analog use in swe-  
691 den—intoxication cases involving 3-meo-pcp and 4-meo-pcp from the  
692 strida project, Clinical Toxicology 53 (2015) 856–864.
- 693 [103] M. B  ckberg, O. Beck, K.-H. J  nsson, A. Helander, Opioid intoxica-  
694 tions involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from  
695 the swedish strida project, Clinical Toxicology 53 (2015) 609–617.
- 696 [104] A. Helander, O. Beck, M. B  ckberg, Intoxications by the dissociative  
697 new psychoactive substances diphenidine and methoxphenidine, Clin-  
698 ical toxicology 53 (2015) 446–453.
- 699 [105] A. Helander, M. B  ckberg, Epidemiology of nps based confirmed over-  
700 dose cases: the strida project, in: New Psychoactive Substances,  
701 Springer, 2018, pp. 461–473.
- 702 [106] M. B  ckberg, K.-H. J  nsson, O. Beck, A. Helander, Investigation of  
703 drug products received for analysis in the swedish strida project on new  
704 psychoactive substances, Drug testing and analysis 10 (2018) 340–349.

- 705 [107] O. Beck, L. Franzen, M. Bäckberg, P. Signell, A. Helander, Intoxi-  
706 cations involving mdpv in sweden during 2010–2014: results from the  
707 strida project, *Clinical toxicology* 53 (2015) 865–873.
- 708 [108] K. Miotto, J. Striebel, A. K. Cho, C. Wang, Clinical and pharmacolog-  
709 ical aspects of bath salt use: a review of the literature and case reports,  
710 *Drug and alcohol dependence* 132 (2013) 1–12.
- 711 [109] I. M. McIntyre, R. D. Gary, S. Joseph, R. Stabley, A fatality related to  
712 the synthetic opioid u-47700: postmortem concentration distribution,  
713 *Journal of Analytical Toxicology* 41 (2017) 158–160.
- 714 [110] A. Helander, M. Bäckberg, O. Beck, Intoxications involving the fen-  
715 tanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfen-  
716 tanyl: results from the swedish strida project, *Clinical Toxicology* 54  
717 (2016) 324–332.
- 718 [111] M. Bäckberg, L. Tworek, O. Beck, A. Helander, Analytically confirmed  
719 intoxications involving mdmb-chmica from the strida project, *Journal*  
720 *of medical toxicology* 13 (2017) 52–60.
- 721 [112] B. K. Logan, A. L. Mohr, M. Friscia, A. J. Krotulski, D. M. Papsun,  
722 S. L. Kacinko, J. D. Roper-Miller, M. A. Huestis, Reports of adverse  
723 events associated with use of novel psychoactive substances, 2013–2016:  
724 a review, *Journal of Analytical Toxicology* 41 (2017) 573–610.
- 725 [113] P. Adamowicz, D. Zuba, Fatal intoxication with methoxetamine, *Jour-*  
726 *nal of Forensic Sciences* 60 (2015) S264–S268.
- 727 [114] M. Bäckberg, O. Beck, P. Hulten, J. Rosengren-Holmberg, A. Helander,  
728 Intoxications of the new psychoactive substance 5-(2-aminopropyl) in-  
729 dole (5-it): a case series from the swedish strida project, *Clinical*  
730 *toxicology* 52 (2014) 618–624.
- 731 [115] R. Kronstrand, G. Thelander, D. Lindstedt, M. Roman, F. Kugelberg,  
732 Fatal intoxications associated with the designer opioid ah-7921, *Journal*  
733 *of analytical toxicology* 38 (2014) 599–604.
- 734 [116] A. Cannaert, E. Sparkes, E. Pike, J. L. Luo, A. Fang, R. C. Kevin,  
735 R. Ellison, R. Gerona, S. D. Banister, C. P. Stove, Synthesis and

- in vitro cannabinoid receptor 1 activity of recently detected synthetic cannabinoids 4f-mdmb-bica, 5f-mpp-pica, mmb-4en-pica, cumyl-cbmica, adb-binaca, app-binaca, 4f-mdmb-binaca, mdmb-4en-pinaca, a-chminaca, 5f-ab-p7aica, 5f-mdmb-p7aica, and 5f-ap7aica, ACS Chemical Neuroscience 11 (2020) 4434–4446.
- [117] A. Ametovski, C. Macdonald, J. J. Manning, S. S. Haneef, M. Santiago, L. Martin, E. Sparkes, A. Reckers, R. R. Gerona, M. Connor, et al., Exploring stereochemical and conformational requirements at cannabinoid receptors for synthetic cannabinoids related to sdb-006, 5f-sdb-006, cumyl-pica, and 5f-cumyl-pica, ACS Chemical Neuroscience 11 (2020) 3672–3682.
- [118] V. Shevyrin, V. Melkozerov, G. W. Endres, Y. Shafran, Y. Morzherin, On a new cannabinoid classification system: a sight on the illegal market of novel psychoactive substances, Cannabis and Cannabinoid Research 1 (2016) 186–194.
- [119] N. I. o. D. A. N. I. o. H. U. D. o. H. , H. Services, Cannabis (marijuana) drugfacts, 2022. URL: <https://nida.nih.gov/publications/drugfacts/cannabis-marijuana#ref>.
- [120] E. Y. Chung, H. J. Cha, H. K. Min, J. Yun, Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists, Archives of Pharmacal Research 44 (2021) 402–413.
- [121] S. Sachdev, S. D. Banister, M. Santiago, C. Bladen, M. Kassiou, M. Connor, Differential activation of g protein-mediated signaling by synthetic cannabinoid receptor agonists, Pharmacology research & perspectives 8 (2020) e00566.
- [122] M. Patel, J. J. Manning, D. B. Finlay, J. A. Javitch, S. D. Banister, N. L. Grimsey, M. Glass, Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists, Biochemical Pharmacology 175 (2020) 113871.
- [123] Z. Hassan, O. G. Bosch, D. Singh, S. Narayanan, B. V. Kasinather, E. Seifritz, J. Kornhuber, B. B. Quednow, C. P. Müller, Novel psychoactive substances—recent progress on neuropharmacological mechanisms of action for selected drugs, Frontiers in psychiatry 8 (2017) 152.

- 770 [124] H. Chung, J. Lee, E. Kim, Trends of novel psychoactive substances  
771 (npss) and their fatal cases, *Forensic Toxicology* 34 (2016) 1–11.
- 772 [125] V. L. Alves, J. L. Gonçalves, J. Aguiar, H. M. Teixeira, J. S. Câmara,  
773 The synthetic cannabinoids phenomenon: from structure to toxicolog-  
774 ical properties. a review, *Critical Reviews in Toxicology* 50 (2020)  
775 359–382.
- 776 [126] A. Giorgetti, F. P. Busardò, R. Tittarelli, V. Auwärter, R. Giorgetti,  
777 Post-mortem toxicology: a systematic review of death cases involving  
778 synthetic cannabinoid receptor agonists, *Frontiers in Psychiatry* 11  
779 (2020) 464.
- 780 [127] T. Coccini, U. De Simone, D. Lonati, G. Scaravaggi, M. Marti, C. Lo-  
781 catelli, Mam-2201, one of the most potent—naphthoyl indole deriva-  
782 tive—synthetic cannabinoids, exerts toxic effects on human cell-based  
783 models of neurons and astrocytes, *Neurotoxicity Research* 39 (2021)  
784 1251–1273.
- 785 [128] M. Valento, J. Lebin, Emerging drugs of abuse: synthetic cannabinoids,  
786 phenylethylamines (2c drugs), and synthetic cathinones, *Clinical Pe-  
787 diatric Emergency Medicine* 18 (2017) 203–211.
- 788 [129] R. Kikura-Hanajiri, New designer drugs in japan, in: *Neuropathology  
789 of drug addictions and substance misuse*, Elsevier, 2016, pp. 1055–1065.
- 790 [130] J. Trecki, R. R. Gerona, M. D. Schwartz, et al., Synthetic cannabinoid-  
791 related illnesses and deaths, *N Engl J Med* 373 (2015) 103–107.
- 792 [131] S. D. Banister, M. Longworth, R. Kevin, S. Sachdev, M. Santiago,  
793 J. Stuart, J. B. Mack, M. Glass, I. S. McGregor, M. Connor, et al.,  
794 Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5f-  
795 ambica, 5f-amb, 5f-adb, amb-fubinaca, mdmb-fubinaca, mdmb-chmica,  
796 and their analogues, *ACS Chemical Neuroscience* 7 (2016) 1241–1254.
- 797 [132] C. Hess, C. T. Schoeder, T. Pillaiyar, B. Madea, C. E. Müller, Pharma-  
798 cological evaluation of synthetic cannabinoids identified as constituents  
799 of spice, *Forensic toxicology* 34 (2016) 329–343.

- [133] D. Rudin, M. E. Liechti, D. Luethi, Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics, *Experimental neurology* 343 (2021) 113778.
- [134] S. Elliott, J. Evans, A 3-year review of new psychoactive substances in casework, *Forensic science international* 243 (2014) 55–60.
- [135] S. Zaami, R. Giorgetti, S. Pichini, F. Pantano, E. Marinelli, F. Busardò, Synthetic cathinones related fatalities: an update, *Eur Rev Med Pharmacol Sci* 22 (2018) 268–274.
- [136] L. Hondebrink, A. Zwartsen, R. H. Westerink, Effect fingerprinting of new psychoactive substances (nps): What can we learn from in vitro data?, *Pharmacology & therapeutics* 182 (2018) 193–224.
- [137] A. Rickli, D. Luethi, J. Reinisch, D. Buchy, M. C. Hoener, M. E. Liechti, Receptor interaction profiles of novel n-2-methoxybenzyl (nbome) derivatives of 2, 5-dimethoxy-substituted phenethylamines (2c drugs), *Neuropharmacology* 99 (2015) 546–553.
- [138] A. J. Eshleman, K. M. Wolfrum, J. F. Reed, S. O. Kim, R. A. Johnson, A. Janowsky, Neurochemical pharmacology of psychoactive substituted n-benzylphenethylamines: High potency agonists at 5-HT<sub>2A</sub> receptors, *Biochemical pharmacology* 158 (2018) 27–34.
- [139] L. Simmler, A. Rickli, M. Hoener, M. Liechti, Monoamine transporter and receptor interaction profiles of a new series of designer cathinones, *Neuropharmacology* 79 (2014) 152–160.
- [140] M. M. Vandeputte, N. Verougstraete, D. Walther, G. C. Glatfelter, J. Malfliet, M. H. Baumann, A. G. Verstraete, C. P. Stove, First identification, chemical analysis and pharmacological characterization of n-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass, *Archives of Toxicology* 96 (2022) 1865–1880.
- [141] M. M. Vandeputte, M. Persson, D. Walther, S. Vikingsson, R. Kronstrand, M. H. Baumann, H. Gréen, C. P. Stove, Characterization of recent non-fentanyl synthetic opioids via three different in vitro  $\mu$ -opioid receptor activation assays, *Archives of Toxicology* 96 (2022) 877–897.

- 833 [142] S. Salle, S. Bodeau, A. Dhersin, M. Ferdonnet, R. Goncalves,  
834 M. Lenski, B. Lima, M. Martin, J. Outreville, J. Vaucel, et al., Novel  
835 synthetic opioids: A review of the literature, *Toxicologie Analytique*  
836 *et Clinique* 31 (2019) 298–316.
- 837 [143] N. C. f. H. S. CDC, U.s. overdose deaths in 2021 increased half as much  
838 as in 2020 - but are still up 15%, 2022. URL: [https://www.cdc.gov/  
839 nchs/pressroom/nchs\\_press\\_releases/2022/202205.htm](https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm).
- 840 [144] C. for Disease Control, Prevention, Understanding the epidemic, 2021.  
841 URL: <https://www.cdc.gov/drugoverdose/epidemic/index.html>.
- 842 [145] C. L. Mattson, L. J. Tanz, K. Quinn, M. Kariisa, P. Patel, N. L. Davis,  
843 Trends and geographic patterns in drug and synthetic opioid overdose  
844 deaths—united states, 2013–2019, *Morbidity and Mortality Weekly*  
845 *Report* 70 (2021) 202.
- 846 [146] M. P. Prekupec, P. A. Mansky, M. H. Baumann, Misuse of novel  
847 synthetic opioids: a deadly new trend, *Journal of addiction medicine*  
848 11 (2017) 256.
- 849 [147] M. H. Baumann, S. Majumdar, V. Le Rouzic, A. Hunkele, R. Uprety,  
850 X. P. Huang, J. Xu, B. L. Roth, Y.-X. Pan, G. W. Pasternak, Pharma-  
851 cological characterization of novel synthetic opioids (nso) found in the  
852 recreational drug marketplace, *Neuropharmacology* 134 (2018) 101–  
853 107.
- 854 [148] I. Tabarra, S. Soares, T. Rosado, J. Gonçalves, Â. Luís, S. Malaca,  
855 M. Barroso, T. Keller, J. Restolho, E. Gallardo, Novel synthetic  
856 opioids–toxicological aspects and analysis, *Forensic Sciences Research*  
857 4 (2019) 111–140.
- 858 [149] N. Allibe, F. Billault, C. Moreau, A. Marchard, Y. Gaillard, G. Hoizey,  
859 H. Eysseric-Guerin, N. Milan, Ocfentanil in france: seven case reports  
860 (2016–2018), *Toxicologie Analytique et Clinique* 31 (2019) 317–322.
- 861 [150] S. Darke, A. Peacock, J. Dufou, M. Farrell, J. Lappin, Characteristics  
862 of fatal ‘novel’synthetic opioid toxicity in australia, *Drug and alcohol*  
863 *dependence* 232 (2022) 109292.



- 864 [151] L. Karila, M. Marillier, B. Chaumette, J. Billieux, N. Franchitto,  
865 A. Benyamina, New synthetic opioids: Part of a new addiction land-  
866 scape, *Neuroscience & Biobehavioral Reviews* 106 (2019) 133–140.
- 867 [152] B. Lovrecic, M. Lovrecic, B. Gabrovec, M. Carli, M. Pacini, A. G.  
868 Maremmani, I. Maremmani, Non-medical use of novel synthetic opi-  
869 oids: a new challenge to public health, *International journal of envi-  
870 ronmental research and public health* 16 (2019) 177.
- 871 [153] A. Y. Simão, M. Antunes, E. Cabral, P. Oliveira, L. M. Rosendo, A. T.  
872 Brinca, E. Alves, H. Marques, T. Rosado, L. A. Passarinha, et al.,  
873 An update on the implications of new psychoactive substances in pub-  
874 lic health, *International journal of environmental research and public  
875 health* 19 (2022) 4869.